{"DataElement":{"publicId":"13341064","version":"1","preferredName":"Treating Investigator Treatment of Choice Code","preferredDefinition":"A coded response to indicate the best treatment as determined by the study investigator.","longName":"13341000v1.00:13341021v1.00","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"13341000","version":"1","preferredName":"Treating Investigator Treatment of Choice","preferredDefinition":"The study investigator in charge of administering treatment to study participants.:The standard or best treatment, based upon a set of criteria appropriate for a particular patient.","longName":"13340998v1.00:13340999v1.00","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"13340998","version":"1","preferredName":"Treating Investigator","preferredDefinition":"The study investigator in charge of administering treatment to study participants.","longName":"C198656","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treating Investigator","conceptCode":"C198656","definition":"The study investigator in charge of administering treatment to study participants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9110A70-D232-2D66-E053-731AD00A57B0","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"FINCHAMB","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"13340999","version":"1","preferredName":"Treatment of Choice","preferredDefinition":"The standard or best treatment, based upon a set of criteria appropriate for a particular patient.","longName":"C198657","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treatment of Choice","conceptCode":"C198657","definition":"The standard or best treatment, based upon a set of criteria appropriate for a particular patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9110A70-D233-2D66-E053-731AD00A57B0","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"FINCHAMB","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9110A70-D234-2D66-E053-731AD00A57B0","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"FINCHAMB","dateModified":"2023-04-13","changeDescription":null,"administrativeNotes":"Curated for SWOG SQ (2207). BF;","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13341021","version":"1","preferredName":"Treatment of Choice Code","preferredDefinition":"The standard or best treatment, based upon a set of criteria appropriate for a particular patient._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"13341021v1.00","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":null,"ValueMeaning":{"publicId":"13341028","version":"1","preferredName":"Arm 3: Tafasitamab + Lenalidomide + Zanubrutinib","longName":"13341028v1.00","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages._A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells._An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","context":"SWOG","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Three","conceptCode":"C66834","definition":"A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Tafasitamab","conceptCode":"C95768","definition":"An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Zanubrutinib","conceptCode":"C141428","definition":"An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F911F5A9-CA83-5A41-E053-731AD00A44E0","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"JKNABLE","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F911F5A9-CA84-5A41-E053-731AD00A44E0","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"FINCHAMB","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"1","valueDescription":null,"ValueMeaning":{"publicId":"13341058","version":"1","preferredName":"Arm 1: Tafasitamab + Lenalidomide + Tazemetostat","longName":"13341058v1.00","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study._The smallest natural number and quantity it denotes: a single entity, unit, or object._An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages._A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells._An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"One","conceptCode":"C66832","definition":"The smallest natural number and quantity it denotes: a single entity, unit, or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Tafasitamab","conceptCode":"C95768","definition":"An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tazemetostat","conceptCode":"C107506","definition":"An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9138CB9-5DC4-26DB-E053-731AD00ADF1C","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-11","modifiedBy":"JKNABLE","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9138CB9-5DC5-26DB-E053-731AD00ADF1C","beginDate":"2023-04-11","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-11","modifiedBy":"JKNABLE","dateModified":"2023-04-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13341020","version":"1","preferredName":"Treatment of Choice Code","preferredDefinition":"The standard or best treatment, based upon a set of criteria appropriate for a particular patient._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"13341020v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treatment of Choice","conceptCode":"C198657","definition":"The standard or best treatment, based upon a set of criteria appropriate for a particular patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9117548-E2DD-3E3E-E053-731AD00A6BD1","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"FINCHAMB","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9117548-E2DE-3E3E-E053-731AD00A6BD1","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"FINCHAMB","dateModified":"2023-04-13","changeDescription":null,"administrativeNotes":"Curated for SWOG S2207. BF;","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Treating Investigator's Treatment of Choice","url":null,"context":"SWOG"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F913FA04-3C27-382D-E053-731AD00A4852","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeDescription":null,"administrativeNotes":"4/11/23 Curated for SWOG (S2207). BF","unresolvedIssues":null,"deletedIndicator":"No"}}